Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Alan K. Davis, Frederick S. Barrett, Sara So, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 437-446
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
A complex systems perspective on psychedelic brain action
Manesh Girn, Fernando E. Rosas, Richard E. Daws, et al.
Trends in Cognitive Sciences (2023) Vol. 27, Iss. 5, pp. 433-445
Closed Access | Times Cited: 42
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 22
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
Distinctive But Not Exceptional: The Risks of Psychedelic Ethical Exceptionalism
Katherine Cheung, Brian D. Earp, Kyle Patch, et al.
The American Journal of Bioethics (2025) Vol. 25, Iss. 1, pp. 16-28
Closed Access | Times Cited: 14
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Gabrielle Agin-Liebes, Trevor Forrest Haas, Rafael Lancelotta, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 543-552
Open Access | Times Cited: 95
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Monnica T. Williams, Alan K. Davis, Yitong Xin, et al.
Drugs Education Prevention and Policy (2020) Vol. 28, Iss. 3, pp. 215-226
Open Access | Times Cited: 77
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 44
Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca
Gabrielle Agin-Liebes, Richard J. Zeifman, Jason B. Luoma, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 295-308
Open Access | Times Cited: 38
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility
Max Wolff, Lea J. Mertens, Marie Walter, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 3, pp. 387-408
Open Access | Times Cited: 38
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 733-748
Open Access | Times Cited: 33
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
Richard J. Zeifman, Anne Catherine Wagner, Candice M. Monson, et al.
Journal of Affective Disorders (2023) Vol. 334, pp. 100-112
Open Access | Times Cited: 29
Restructuring insight: An integrative review of insight in problem-solving, meditation, psychotherapy, delusions and psychedelics
Kadi Tulver, Karl Kristjan Kaup, Ruben Laukkonen, et al.
Consciousness and Cognition (2023) Vol. 110, pp. 103494-103494
Open Access | Times Cited: 28
Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder
Richard J. Zeifman, Hannes Kettner, Stephen Ross, et al.
European journal of psychotraumatology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Effects of DMT on mental health outcomes in healthy volunteers
Christopher Timmermann, Richard J. Zeifman, David Erritzøe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Clinically relevant acute subjective effects of psychedelics beyond mystical experience
David B. Yaden, Sean P. Goldy, Brandon Weiss, et al.
Nature Reviews Psychology (2024) Vol. 3, Iss. 9, pp. 606-621
Closed Access | Times Cited: 12
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Brandon Weiss, Leor Roseman, Bruna Giribaldi, et al.
International Journal of Mental Health and Addiction (2024) Vol. 22, Iss. 2, pp. 806-841
Open Access | Times Cited: 11
An Integrated theory of false insights and beliefs under psychedelics
H. T. McGovern, Hilary Jane Grimmer, Manoj K. Doss, et al.
Communications Psychology (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 10
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Jacob S. Aday, David Horton, Gisele Fernandes‐Osterhold, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1517-1526
Closed Access | Times Cited: 9
Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial
Shakila Meshkat, Richard J. Zeifman, Kathleen E. Stewart, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313741-e0313741
Open Access | Times Cited: 1
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Malin V. Uthaug, Alan K. Davis, Trevor Forrest Haas, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 3, pp. 309-320
Open Access | Times Cited: 49
Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color
Alan K. Davis, Yitong Xin, Nathan D. Sepeda, et al.
Chronic Stress (2021) Vol. 5
Open Access | Times Cited: 46
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Richard J. Zeifman, Nikhita Singhal, Leah Breslow, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 436-451
Open Access | Times Cited: 45
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Nadav Liam Modlin, Tammy M. Miller, James Rucker, et al.
Journal of Affective Disorders (2023) Vol. 326, pp. 18-25
Closed Access | Times Cited: 18
Psychedelics and the ‘inner healer’: Myth or mechanism?
Joseph Peill, M. Marguilho, David Erritzøe, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 5, pp. 417-424
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top